Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Neurotherapeutics

Topics

Biology

Neuroscience

Chemistry

Medicine

Materials Science

Show all topics

DOI

10.1007/s13311-022-01308-6

License

CC-BY

Other Formats

PDF